BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.110
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
1.130
+0.020 (1.80%)
After-hours: Dec 5, 2025, 4:12 PM EST
BioRestorative Therapies Revenue
BioRestorative Therapies had revenue of $11.80K in the quarter ending September 30, 2025, a decrease of -94.95%. This brings the company's revenue in the last twelve months to $383.40K, up 1.70% year-over-year. In the year 2024, BioRestorative Therapies had annual revenue of $401.00K with 175.03% growth.
Revenue (ttm)
$383.40K
Revenue Growth
+1.70%
P/S Ratio
24.86
Revenue / Employee
$34,855
Employees
11
Market Cap
9.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
| Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
| Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
| Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
| Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
| Dec 31, 2019 | 130.00K | 19.00K | 17.12% |
| Dec 31, 2018 | 111.00K | 30.00K | 37.04% |
| Dec 31, 2017 | 81.00K | 44.65K | 122.80% |
| Dec 31, 2016 | 36.36K | -592.56K | -94.22% |
| Dec 31, 2015 | 628.92K | 212.92K | 51.18% |
| Dec 31, 2014 | 416.00K | 414.32K | 24,661.67% |
| Dec 31, 2013 | 1.68K | -13.91K | -89.22% |
| Dec 31, 2012 | 15.59K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BRTX News
- 23 days ago - BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 - GlobeNewsWire
- 5 weeks ago - BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market - GlobeNewsWire
- 6 weeks ago - BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio - GlobeNewsWire
- 7 weeks ago - BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit - GlobeNewsWire
- 2 months ago - BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show” - GlobeNewsWire
- 2 months ago - BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market - GlobeNewsWire
- 4 months ago - BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha